[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646372":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":10,"centralContacts":31,"locations":10,"responsibleParty":37,"collaborators":40,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":91,"sex":92,"minAge":93,"maxAge":10,"enrollmentInfo":94,"targetDuration":10,"studyType":97,"phases":10,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":106,"whyStopped":10,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":10},{"fullName":5,"class":6},"Erasmus Medical Center","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"PTC",null,"Viremic PWH (HIV-RNA \\>1000c\u002FmL) before ART initiation. Plasma HIV-RNA off ART ≤400c\u002FmL at least 2 times at ≥24weeks apart and at ≥2\u002F3rds of HIV-RNA measurements. Elite PTC with ≤50c\u002FmL will be identified",[13],"Other: No Intervention: Observational Cohort",{"label":15,"type":10,"description":16,"interventionNames":17},"Post intervention controller (PIC)","PWH from ATI or MAP studies who meet the PTC criteria as per ATI\u002FMAP study defined. Additional stratification occurs according to the duration of and level of suppressed plasma HIV-RNA (e.g. ≤400c\u002FmL off ART at least 2 times for ≥8 weeks apart). This is done to streamline PIC definitions and capture PIC in MAP studies with an ART pause of less than 24 weeks.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Controls","non-controllers (NC) with plasma HIV-RNA \\>1000 c\u002FmL after ART interruption",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Suppressors","viremic PWH (HIV-RNA \\>1000c\u002FmL) before ART initiation who became HIV-RNA \\\u003C50c\u002FmL suppressed on ART, remained on ART, and never had viral rebound.",[13],[27],{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"No Intervention: Observational Cohort","No intervention (observational cohort)",[19,9,15,23],[32],{"name":33,"role":34,"phone":35,"phoneExt":10,"email":36},"Casper Rokx","CONTACT","+31618069137","c.rokx@erasmusmc.nl",{"type":38,"investigatorFullName":33,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Ass. Prof. Dr.",[41,44,46,48,50,52,54,56,59,61,63,65,67,69,71,73,75,77,79,81],{"name":42,"class":43},"EU2Cure consortium","UNKNOWN",{"name":45,"class":6},"Radboud University Medical Center",{"name":47,"class":43},"European Aids Treatment Group (EATG), Brussels, Belgium",{"name":49,"class":6},"University Hospital, Ghent",{"name":51,"class":6},"University Ghent",{"name":53,"class":6},"Oslo University Hospital",{"name":55,"class":6},"Charite University, Berlin, Germany",{"name":57,"class":58},"Institut Pasteur","INDUSTRY",{"name":60,"class":6},"University of Aarhus",{"name":62,"class":6},"IrsiCaixa",{"name":64,"class":43},"Fundació Lluita contra les Infeccions",{"name":66,"class":6},"IRCCS San Raffaele",{"name":68,"class":6},"Imperial College London",{"name":70,"class":6},"University of Oxford",{"name":72,"class":6},"Guy's and St Thomas' NHS Foundation Trust",{"name":74,"class":43},"Chelsea and Westminster Hospital, UK",{"name":76,"class":6},"Pomeranian Medical University Szczecin",{"name":78,"class":6},"Hospital Universitari Vall d'Hebron Research Institute",{"name":80,"class":6},"Medical University of Warsaw",{"name":82,"class":6},"Centre Hospitalier Universitaire Vaudois","100646372","biomarkers-for-post-treatment-control-in-hiv-international-study-of-the-eu2cure-research-consortium-phase-i-100646372",false,"NCT07692295","Biomarkers for Post-treatment Control in HIV: International Study of the EU2Cure Research Consortium (Phase I)","Biomarkers for Post-treatment Control in HIV: International Multicenter Study of the EU2Cure Research Consortium (EU2Control)","EU2Control","Inclusion Criteria:\n\n1. PTC: Viremic people living with HIV (HIV-RNA \\>1000c\u002FmL) before ART initiation. Plasma HIV-RNA off ART ≤400c\u002FmL at least 2 times at ≥24weeks apart and at ≥2\u002F3rds of HIV-RNA measurements. Elite PTC with ≤50c\u002FmL will be identified.\n2. Post intervention controller (PIC): People living with HIV from ATI or MAP studies who meet the PTC criteria as per ATI\u002FMAP study defined. Additional stratification occurs according to the duration of and level of suppressed plasma HIV-RNA (e.g. ≤400c\u002FmL off ART at least 2 times for ≥8 weeks apart). This is done to streamline PIC definitions and capture PIC inMAP studies with an ART pause of less than 24 weeks.\n3. Controls: non-controllers (NC) with plasma HIV-RNA \\>1000 c\u002FmL after ART interruption.\n4. Suppressors: viremic people living with HIV (HIV-RNA \\>1000c\u002FmL) before ART initiation who became HIV-RNA \\\u003C50c\u002FmL suppressed on ART, remained on ART, and never had viral rebound.\n\nExclusion Criteria:\n\n* 1.Documented refusal of data use for research",true,"ALL","16 Years",{"count":95,"type":96},200,"ESTIMATED","OBSERVATIONAL","Antiretroviral therapy (ART) has transformed HIV from a deadly disease into a lifelong infection that can be controlled. Nevertheless, in the majority of people living with HIV (PWH), discontinuation of ART results in viral rebound due to a latent proviral reservoir. Rarely, individuals known as post-treatment controllers (PTC) demonstrate prolonged viral control even after ceasing ART. Investigating the underlying mechanisms driving this sustained viral control has been a goal for the HIV research community. However, previous studies have been hindered by the scarcity of PTC cases, thereby restricting the potential for associative and translational research. Consequently, the aim of this study is to collect and meta-analyse the data from prior trials where PTC have been identified, as well as to retrospectively identify PTC from the routine care outside trials in a multicentre, multinational study called EU2Control. The aggregated clinical data, and the already collected material from trials where PWH consented for use in additional studies on HIV, will be analyzed with the goal to identify predictive biomarkers for sustained viral control. This study will be part of the research line on HIV cure from an ongoing collaborative consortium (EU2Cure). The first phase of this research line involves a retrospective cohort for meta-analysis and establishment of a biobank.",[100],"HIV",[100,102,103,104,105],"Post-treatment control","Post-intervention control","biobank","biomarkers","NOT_YET_RECRUITING","2026-07-07",{"date":109,"type":110},"2026-07-09","ACTUAL",{"date":112,"type":96},"2026-10",{"date":114,"type":96},"2027-12",{"name":5,"class":6}]